PSYCH Symposium returned at the British Museum on 6 July to explore how psychedelic medicines can innovate healthcare – from mental health to eating disorders and...
PSYCH Symposium: London 2023 brought together key stakeholders to explore the landscape of psychedelic medicine at the British Museum on Thursday, 6 July.
Psychedelic Medicine Investment Fund Negev Capital is aiming to innovate mental healthcare in Europe by providing funding to companies on the cutting edge of psychedelic research.
Awakn Life Sciences has completed the sale of Awakn London Limited Ltd.,
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of experts will discuss how psychedelics could innovate eating disorder care.
CEO of Cybin Inc.
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
The high of MDMA (a.k.a.
For the first time, the U.S.
Psychedelics stand at a pivotal crossroads in mental health, offering the prospect of novel therapeutic avenues to address multiple mental conditions, from treatment-resistant depression to post-traumatic...
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of changemakers and MEPs will discuss the future of psychedelic healthcare in...